Here's Why You Should Add BrightSpring Stock to Your Portfolio Now

Headquartered in Louisville, KY, the company holds a market capitalization of $12.16 billion. BTSG is a national home and community-based healthcare services platform integrating pharmacy and provider care for medically complex patients across Medicare, Medicaid and commercial payors. The company serves 50 states and focuses on seniors and specialty populations in lower-cost home and community settings. Its forward P/E ratio of 41.80 is significantly higher than the industry average of 16.74.

Image Source: Zacks Investment Research

Let’s delve deeper.

BTSG’s Growth Drivers

Specialty and Infusion Remain Key Growth Engines: Specialty and Infusion continued to lead Pharmacy Solutions, with second-quarter 2026 revenues rising 30% year over year to $2.9 billion, supported by branded LDDs, new launches, generic growth, fee-for-service programs and strong execution. Script growth reached 31%, while BrightSpring added two ultra-narrow LDDs, taking its portfolio to 155, with 12 LDDs launched year to date. Infusion delivered strong volume growth, including more than 20% growth in acute infusion and nearly 20% in chronic infusion. The company plans to expand into 12-15 additional states over the next five years, while concierge programs, AI-enabled intake and greater integration with Pharmacy Solutions should support longer-term growth.

Provider Services Momentum and Integration: Provider Services revenues increased 30% year over year to $466 million, led by Home Health Care, where revenues jumped 51% on strong census growth, de novo expansion, preferred MA/ACO contracts and Amedisys/LHC contributions. The acquired branches contributed $78 million of revenues and $8 million of adjusted EBITDA in the second quarter, while BrightSpring raised its 2026 EBITDA contribution expectation for these assets to approximately $35 million as integration progresses well. Nearly 95% of Home Health branches now carry four-star or better ratings, supporting referral growth and payer relationships.

Platform Scale and Margin Conversion: BrightSpring’s integrated pharmacy and provider platform serves large home and community healthcare markets where payors seek coordinated, lower-cost care. Second-quarter 2026 results showed broad-based growth and faster adjusted EBITDA expansion, driven by purchasing efficiencies, standardized operations, technology and automation. Management expects EBITDA to outpace revenue growth as efficiencies and mix improve, with approximately $600 million in operating cash flow and leverage below 2x before acquisitions to support disciplined reinvestment and growth.

BTSG Stock: Key Risks to Watch

IRA-Related Revenue Pressure: IRA-related reimbursement changes and brand-to-generic conversions continue to weigh on reported pharmacy revenues despite improving volumes and profitability. Home and Community Pharmacy absorbed an approximately $50 million IRA impact in the second quarter of 2026, with about $45 million expected in each remaining quarter, implying a roughly $200 million full-year impact. While higher volume, mix and execution supported BrightSpring’s raised 2026 guidance, reimbursement resets may create uneven quarterly growth and complicate comparisons until the business establishes a cleaner base.

Home and Community Pharmacy Revenue Drag: Home and Community Pharmacy remains affected by customer exits and reimbursement pressure, although EBITDA performance is improving. Second-quarter 2026 revenues were impacted by the IRA and exits from uneconomic customers. Controllable customer retention reached a record high, while dispensing accuracy was 99.9% and order completeness was 99%. Despite all-time-high controllable retention and strong operational metrics, revenue recovery will depend on replacing lost volume with more attractive business, while automation and service improvements help protect profitability.

BTSG’s Estimate Trend

BrightSpring has been witnessing a positive estimate revision trend for 2026. In the past 60 days, the Zacks Consensus Estimate for its earnings has moved north 11 cents to $1.78 per share, implying a gain of 78% from the prior-year reported level.

The Zacks Consensus Estimate for 2026 revenues is pegged at $15.24 billion, suggesting an 18.1% improvement from the year-ago reported number.

Other Key Picks

Some other top-ranked stocks from the broader medical space are Globus Medical GMED, West Pharmaceutical WST and The Cooper Companies COO.

Globus Medical, currently sporting a Zacks Rank #1, reported a second-quarter 2026 adjusted earnings per share (EPS) of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%. You can see the complete list of today’s Zacks #1 Rank stocks here.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

The Cooper Companies, carrying a Zacks Rank #2 at present, reported a second-quarter fiscal 2026 adjusted EPS of $1.21, which beat the Zacks Consensus Estimate by 10.00%. Revenues of $1.08 billion beat the Zacks Consensus Estimate by 2.6%.

COO has an estimated long-term earnings growth rate of 8.3%. COO’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 5.8%.

Beyond Nvidia: AI's Second Wave Is Here

The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research